Posted by Michael Wonder on 17 Aug 2023
Amicus Therapeutics announces approval and launch of new Pompe disease therapy in the United Kingdom
15 August 2023 - Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) approved for adults living with late-onset Pompe disease in Great Britain.
Amicus Therapeutics today announced that the MHRA of the United Kingdom has granted marketing authorisations for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for adults living with late-onset Pompe disease (acid α-glucosidase deficiency).
